
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx is a medical technology company that has a promising future based on its strong fundamentals. With an expected sequential improvement in year-over-year revenue growth through 2026 and a focused U.S. strategy, the company is poised for a return to growth in both domestic and international markets. Additionally, Pulmonx's cost restructuring initiatives have resulted in improved margins and a lower net loss, making it a potential investment opportunity.
Bears say
Pulmonx is facing a transitional period as the company refocuses on operational discipline and commercial reacceleration, with fourth quarter revenue declining to $22.6M amid weaker U.S. performance and a net loss of $14.0M. While the company has a solid cash position, future capital pressure could be a concern if U.S. treatment center utilization and patient conversion do not reaccelerate without additional sales force expansion that could compress margins. Key risks include Clinical/Regulatory, Partnership and Financial, Commercial, Legal and Intellectual Property, and Market Share, while potential catalysts include the upcoming earnings cycle and the company's efforts to improve sales productivity and operating expense discipline.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares